Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987058) titled 'RVU120 Rollover Study' on May 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Ryvu Therapeutics SA
Condition:
Advanced Solid Tumors
Acute Myeloid Leukaemia (AML)
High-risk Myelodysplastic Syndrome
Intervention:
Drug: RVU120
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: August 7, 2025
Target Sample Size: 10
Countries of Recruitment:
Poland
Spain
Poland
Spain
To know more, visit https://clinicaltrials.gov/ct2/show/NCT06987058
Disclaimer: Curate...